NCIC CLINICAL TRIALS GROUP

BRAIN

DISEASE SITE COMMITTEE MEETING AGENDA

Hilton Montréal Bonaventure, Montréal, Québec Saturday, April 29, 2006 - 8:30 a.m. – 12:00 p.m. Room: Mont Royal

Chairs: Greg Cairncross and Warren Mason

8:30 a.m.	WELCOME AND INTRODUCTIONS	G. Cairncross
	COMPLETED STUDIES	
8:40 a.m. 8:50 a.m.	CE.2-PCV plus RT vs RT for oligodendroglioma-update CE.3-Temozolomide plus RT vs RT for GBM-update	G. Cairncross W. Mason
	New Trials	
9:00 a.m. 9:15 a.m. 9:45 a.m. 10:00 a.m. 10:15 a.m.	CE.4-RT vs observation for incompletely resected benign meningioma CE.5-RT vs temozolomide for low-grade glioma CE.5 Socio-behavioural questions CE.6-RT vs RT plus temozolomide for elderly GBM IND.162-A phase I/II study of RAD001c plus Temozolomide in GBM IND.170- A phase I/II study of GW572016 in GBM	L. Souhami W. Mason ne/M. Parkinson N. Laperriere W. Mason B. Thiessen
10:30 a.m.	COFFEE BREAK	
	FUTURE NCIC PHASE II/III STUDIES	
10:45 a.m. 11:00 a.m.	Proposed EORTC/NCIC/RTOG trial for newly diagnosed anaplastic astrocytoma Proposed /RTOGNCIC/EORTC trial for anaplastic oligodendroglioma	W. Mason G. Cairncross
	IDEAS AND CONCERNS FOR NEW GLIOMA TRIALS	
11:00 a.m. 11:15 a.m. 11:30 a.m. 11:45 a.m.	Chloroquine with radiotherapy and temozolomide for newly diagnosed GBM Canadian Brain Tumour Tissue Bank CTSU and CTA issues for future intergroup trials Report from the NCIC CTG IND meeting	P. Cano A. Skanda C. O'Callaghan W. Mason
12:00 p.m.	Adjourn	